Blar i forfatter Artikler, rapporter og annet (UB) "Åsvold, Bjørn Olav"

Viser treff 1-2 av 2

    • Intergenerational polygenic obesity risk throughout adolescence in a cross-sectional study design: The HUNT study, Norway 

      Næss, Marit; Sund, Erik; Vie, Gunnhild Åberge; Bjørngaard, Johan Håkon; Åsvold, Bjørn Olav; Holmen, Turid Lingaas; Kvaløy, Kirsti (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-10-14)
      Objective - This study examined the relationship between parental obesity polygenic risk and children’s BMI throughout adolescence. Additionally, from a smaller subsample, the objective was to assess whether parental polygenic risk score (PRS) may act as a proxy for offspring PRS in studies lacking offspring genetic data.<p> <p>Methods - A total of 8,561 parent-offspring (age 13-19 years) trios ...

    • Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition 

      Brumpton, Ben Michael; Fritsche, Lars; Zheng, Jie; Nielsen, Jonas Bille; Mannila, Maria Nastase; Surakka, Ida; Rasheed, Humaira; Vie, Gunnhild Åberge; Graham, Sarah E.; Gabrielsen, Maiken Elvestad; Laugsand, Lars Erik; Aukrust, Pål; Vatten, Lars Johan; Damås, Jan Kristian; Ueland, Thor; Janszky, Imre; Zwart, John-Anker; van't Hooft, Ferdinand M.; Seidah, Nabil Georges; Hveem, Kristian; Willer, Cristen; Smith, George Davey; Åsvold, Bjørn Olav (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-15)
      PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range ...